跳转至内容
Merck
  • Mycophenolic acid mediated disruption of the intestinal epithelial tight junctions.

Mycophenolic acid mediated disruption of the intestinal epithelial tight junctions.

Experimental cell research (2014-02-11)
Muhammad Qasim, Hazir Rahman, Raees Ahmed, Michael Oellerich, Abdul R Asif
摘要

Gastrointestinal toxicity is a common adverse effect of mycophenolic acid (MPA) treatment in organ transplant patients, through poorly understood mechanisms. Phosphorylation of myosin light chain 2 (MLC2) is associated with epithelial tight junction (TJ) modulation which leads to defective epithelial barrier function, and has been implicated in GI diseases. The aim of this study was to investigate whether MPA could induce epithelial barrier permeability via MLC2 regulation. Caco-2 monolayers were exposed to therapeutic concentrations of MPA, and MLC2 and myosin light chain kinase (MLCK) expression were analyzed using PCR and immunoblotting. Epithelial cell permeability was assessed by measuring transepithelial resistance (TER) and the flux of paracellular permeability marker FITC-dextran across the epithelial monolayers. MPA increased the expression of MLC2 and MLCK at both the transcriptional and translational levels. In addition, the amount of phosphorylated MLC2 was increased after MPA treatment. Confocal immunofluorescence analysis showed redistribution of TJ proteins (ZO-1 and occludin) after MPA treatment. This MPA mediated TJ disruption was not due to apoptosis or cell death. Additionally ML-7, a specific inhibitor of MLCK was able to reverse both the MPA mediated decrease in TER and the increase in FITC-dextran influx, suggesting a modulating role of MPA on epithelial barrier permeability via MLCK activity. These results suggest that MPA induced alterations in MLC2 phosphorylation and may have a role in the patho-physiology of intestinal epithelial barrier disruption and may be responsible for the adverse effects (GI toxicity) of MPA on the intestine.

材料
货号
品牌
产品描述

Sigma-Aldrich
葡聚糖 来源于明串珠菌 属, Mr 450,000-650,000
Sigma-Aldrich
葡聚糖 来源于明串珠菌 属, Mr ~70,000
Sigma-Aldrich
葡聚糖 来源于明串珠菌 属, Mr ~40,000
Sigma-Aldrich
荧光素 5(6)-异硫氰酸酯, BioReagent, suitable for fluorescence, mixture of 2 components, ≥90% (HPLC)
Sigma-Aldrich
葡聚糖 来源于肠系膜明串珠菌, average mol wt 9,000-11,000
Sigma-Aldrich
葡聚糖 来源于肠系膜明串珠菌, average mol wt 1,500,000-2,800,000
Sigma-Aldrich
葡聚糖 来源于肠系膜明串珠菌, average mol wt 60,000-76,000
Sigma-Aldrich
葡聚糖 来源于肠系膜明串珠菌, average mol wt 35,000-45,000
Sigma-Aldrich
葡聚糖 来源于明串珠菌 属, Mr ~6,000
Sigma-Aldrich
霉酚酸, ≥98%
Sigma-Aldrich
荧光素 5(6)-异硫氰酸酯, ≥90% (HPLC)
Sigma-Aldrich
葡聚糖 来源于肠系膜明串珠菌, average mol wt 150,000
Sigma-Aldrich
荧光素异硫氰酸酯异构体I, ≥97.5% (HPLC)
Supelco
右旋糖酐, analytical standard, for GPC, 25,000
Sigma-Aldrich
葡聚糖 来源于明串珠菌 属, Mr ~100,000
Supelco
右旋糖酐, analytical standard, for GPC, 5,000
Sigma-Aldrich
霉酚酸, powder, BioReagent, suitable for cell culture
Sigma-Aldrich
葡聚糖 来源于肠系膜明串珠菌, Mr ~200,000
Supelco
右旋糖酐, analytical standard, for GPC, 1,000
Sigma-Aldrich
葡聚糖 来源于明串珠菌 属, Mr 15,000-25,000
Sigma-Aldrich
葡聚糖 来源于肠系膜明串珠菌, Mr ~60,000
Supelco
葡聚糖 来源于肠系膜明串珠菌, analytical standard, for GPC, Mw 670,000
Sigma-Aldrich
右旋糖酐, enzymatic synth.
Sigma-Aldrich
荧光素异硫氰酸酯异构体I, ≥97.5% (HPLC)
Sigma-Aldrich
葡聚糖 溶液 来源于肠系膜明串珠菌, 20 % (w/w) (Autoclaved)
Supelco
右旋糖酐, analytical standard, for GPC, 270,000
Supelco
霉酚酸标准液 CRM 溶液, 1.0 mg/mL in acetonitrile, ampule of 1 mL, certified reference material, Cerilliant®
Supelco
葡聚糖 来源于肠系膜明串珠菌, analytical standard, for GPC, Mw 5,000
Supelco
右旋糖酐, analytical standard, for GPC, 410,000
Sigma-Aldrich
葡聚糖 来源于肠系膜明串珠菌, average mol wt 48,000-90,000